Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Disclosure Information<br />Relationships Relevant to this Session

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

CRYSTAL study design

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Background

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

RAS mutation analysis: BEAMing

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

RAS mutation analysis: BEAMing

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Study profile

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Other RAS mutations: CRYSTAL

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Other RAS mutations: first-line studies

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Comparison of RAS subgroups: <br />efficacy

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Baseline characteristics

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Efficacy: RAS subgroups

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Efficacy: RAS subgroups

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Progression-free survival

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Progression-free survival

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Overall survival

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Overall survival

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Efficacy: RAS subgroups

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Safety: grade 3/4 adverse events

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Conclusions

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Acknowledgments

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting